MedTrace Logo

Trimethoprim-Sulfamethoxazole vs Levofloxacin as Targeted Therapy for Stenotrophomonas Maltophilia Infections: a Retrospective Cohort Study

NCT04639817 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1621

Last updated 2021-04-28

No results posted yet for this study

Summary

This study seeks to compare mortality outcomes of levofloxacin and trimethoprim-sulfamethoxazole treated patients who have Stenotrophomonas maltophilia blood stream or lower respiratory tract infections by retrospectively analyzing a propensity-matched cohort from a large dataset of electronic health record data.

Conditions

  • Stenotrophomonas Infection

Interventions

DRUG

Levofloxacin

Levofloxacin administration

DRUG

trimethoprim-sulfamethoxazole

Trimethoprim-sulfamethoxazole administration

Sponsors & Collaborators

  • Duke University

    collaborator OTHER

  • Emory University

    collaborator OTHER

  • National Institutes of Health Clinical Center (CC)

    lead NIH

Principal Investigators

  • Sameer Kadri, MD · National Institutes of Health (NIH)

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-14
Primary Completion
2021-01-31
Completion
2021-04-27
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04639817 on ClinicalTrials.gov